ReViral, a clinical-stage biopharmaceutical company focused on discovering and developing antiviral therapeutics that target (RSV) respiratory syncytial virus has confirmed the FDA has granted Fast Track designation to Sisunatovir.

Sisunatovir is orally administered and is for the treatment of patients with serious RSV infection. Richmond Pharmacology is proud to have supported the development by conducting the First in Human Study earlier in the drug development.

RSV affects approximately 64 million people and causes approximately 160,000 deaths each year. Fast Track is a process intended to facilitate the development and expediate the review of drug candidates that treat serious conditions and fill an unmet medical need.

Latest news

Futureproofing early phase clinical research for the next generation of investigators.

March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
Read more

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read more

Events

13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event